TLSA
(NASDAQ)
2.60
+0.1000   (+4.00%)
After Hours: 2.50 -0.1000 (-3.85%)
Volume (24h) Market Cap. Day Range 52w Range
150.49K 220.89M 2.43 - 2.62 0.62 - 12.17
Nov-18-20 10:16AM Tiziana Life Sciences PLC ("Tiziana" or the "Company") - PDMR DealingGlobeNewswire
Nov-11-20 02:00AM Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s DiseaseGlobeNewswire
Nov-02-20 03:31AM Tiziana Kicks Off Covid-19 Treatment Trial In Brazil; Stock Up 250% YTDSmarterAnalyst
02:00AM Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal AntibodyGlobeNewswire
Oct-27-20 12:00PM Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)GlobeNewswire
Oct-22-20 07:28AM Tiziana Life's (TLSA) Shares March Higher, Can It Continue?Zacks
Oct-02-20 07:00AM Tiziana Life Sciences Plc (the "Company") - Result of General MeetingGlobeNewswire
Sep-25-20 02:00AM Tiziana Life Sciences Interview to Air on Bloomberg International on The RedChip Money ReportGlobeNewswire
Sep-21-20 09:51AM Tiziana Life Sciences plc: Publication of Research NoteGlobeNewswire
Sep-17-20 02:00AM Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in BrazilGlobeNewswire
Sep-16-20 10:10AM Tiziana Life Sciences PLC (LON:TILS) Insiders Increased Their HoldingsSimply Wall St.
06:00AM Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, Accustem SciencesGlobeNewswire
Sep-16-20 02:00AM Tiziana Life Sciences Plc ("Tiziana" or the "Company") - Demerger of StemPrintER and Distribution in SpecieGlobeNewswire
Aug-28-20 05:30AM Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration StatementGlobeNewswire
Aug-27-20 02:00AM Tiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive InterviewGlobeNewswire
Aug-24-20 08:42AM Tiziana Wins Patent for Potential Covid-19 TreatmentTheStreet.com
03:14AM Tiziana Wins Patent Approval For TZLS-501 Potential Covid-19 TreatmentSmarterAnalyst
Aug-24-20 02:00AM Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseasesGlobeNewswire
Aug-21-20 02:00AM Tiziana Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma and other CancersGlobeNewswire
Aug-20-20 02:00AM Tiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year TermGlobeNewswire
Aug-18-20 06:08AM Tiziana Spikes 25% In Pre-Market On Patent Win For ForalumabSmarterAnalyst
02:00AM Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s DiseaseGlobeNewswire
Aug-11-20 04:00AM Tiziana Life Sciences to Present at BTIG’s Virtual Biotechnology ConferenceGlobeNewswire
Aug-06-20 03:57AM LD Micro:- Announces Preliminary List of Presenters for the LD 500.ACCESSWIRE
Aug-05-20 11:00AM Tiziana Life Sciences plc Announces Closing of $57.25 Million OfferingGlobeNewswire
Aug-04-20 02:00AM Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 PatientsGlobeNewswire
Aug-03-20 02:00AM Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 millionGlobeNewswire
Jul-31-20 12:05PM Why Tiziana Life Sciences' Stock Is Trading Higher TodayBenzinga
12:00PM Tiziana Life Sciences plc: Total Voting RightsGlobeNewswire
Jul-31-20 02:00AM Tiziana Life Sciences plc: Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 PatientsGlobeNewswire
Jul-30-20 11:31AM Tiziana Life Sciences plc: Early notification of proposed admission to the Official List and cancellation of trading on AIMGlobeNewswire
02:00AM Tiziana Life Sciences to Participate in Investor Webinar to Provide Corporate Updates and Q&A Session on July 30, 2020GlobeNewswire
Jul-24-20 02:00AM Exercise of Warrants and Issue of Equity and Total Voting RightsGlobeNewswire
Jul-20-20 10:17AM Tiziana Life Sciences plc ("Tiziana" or the "Company") Director AppointmentGlobeNewswire
Jul-16-20 07:23AM Results of Annual General MeetingGlobeNewswire
02:00AM Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T TherapyGlobeNewswire
Jul-15-20 06:34AM Tesla Hit a New High. No, It Was TLSA. Confused?Barrons.com
04:47AM Tesla Ticker Confusion May Be Aiding Biotech Stock’s RallyBloomberg
Jul-15-20 11:56AM Tiziana Life Sciences plc Change to ADS Ratio - UpdatedGlobeNewswire
08:28AM Tiziana Life Sciences plc Change to ADS RatioGlobeNewswire
Jul-14-20 10:41AM Tiziana Life Sciences PLC (TLSA) Shares March Higher, Can It Continue?Zacks
Jul-10-20 01:41AM Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money ReportGlobeNewswire
Jun-30-20 09:35AM Company News for Jun 30, 2020Zacks
Jun-29-20 03:12AM Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19GlobeNewswire
Jun-19-20 07:41AM The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOsBenzinga
02:00AM Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human DiseasesGlobeNewswire
Jun-18-20 01:50AM Tiziana Life Sciences PLC Directorate ChangeGlobeNewswire
Jun-04-20 02:00AM Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer’s diseaseGlobeNewswire
May-29-20 02:00AM Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancerGlobeNewswire
May-22-20 02:00AM Tiziana Lifesciences Announces Intention to Demerge Its StemPrintER Genomics-Based Personalized Medicine Business as a Separate Listed CompanyGlobeNewswire
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of therapeutics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Milciclib (TZLS-201) that is in phase II clinical trials for epithelial thymic carcinoma and/or thymoma in patients previously treated with chemotherapy; and Foralumab (TZLS-401), a human anti-CD3 antibody, which completed phase IIa clinical trials for autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, primary biliary cholangitis, ulcerative colitis, multiple sclerosis, autoimmune type-1 diabetes, inflammatory bowel diseases, and lupus. It also develops TZLS-501, a human anti IL-6R monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Cap:    |  Volume (24h):